⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Human iPS and Stem Cell Core

The Human iPS & Stem Cell Core Facility is committed to accelerating collaborative studies in stem cell biology. Our know-how encompasses making patient-specific induced pluripotent stem cells (iPSCs) for disease modeling and prospective therapies as well as differentiating them into particular cellular lineages such as neural progenitors, mesenchymal stem cells, endothelial and hematopoietic cells. Our expertise is available to facilitate the development of joint proposals.

Our current stem cell repository includes:

  • hESC lines acquired (NIH approved): H1; H7; H9; H13.B; and H14.
  • iPSC established at the research institute: iPSC line reprogrammed from fibroblasts (ATCC, MRC-5), iPS line with trisomy 21, iPSC with GRIN2B mutation, iPSC line with RA1 mutation.